Biotech fundraising trackerThis link tracks venture biotech fundraisings. You can tell that Series A financing often raise more than our current valuation, despite where we stand (50% into a pivotal Ph. 2, few months away ahead of FDA Breakthrough Therapy dcision, data superior to competition, etc ...).
When the word gets out, our valuation has plenty of upside room on upcoming key events, given that we're already on the exchange. Our patience will be rewarded. Let there be no doubt. Management is invested and have stock options too, so they also have incentives to bring these 15y of innovation and hard work to market.
https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-23